Reaction of C-reactive protein with interleukin-2 receptor α-Chain

1998 ◽  
Vol 125 (6) ◽  
pp. 582-584 ◽  
Author(s):  
P. G. Nazarov
2018 ◽  
Vol 139 (1) ◽  
pp. 12-18 ◽  
Author(s):  
Yukiko Kawaguchi ◽  
Tsuyoshi Nakamaki ◽  
Maasa Abe ◽  
Yuta Baba ◽  
So Murai ◽  
...  

Bendamustine has demonstrated favourable efficacy in relapsed or refractory indolent lymphoma and mantle cell lymphoma. We retrospectively evaluated the pre-treatment clinical and laboratory factors and their correlation with the clinical outcome of these lymphomas. We analysed 53 patients who had been treated with bendamustine alone (n = 6) or rituximab plus bendamustine (n = 47). The overall response rate was 81.1%, with a complete response (CR) rate of 39.6%. The CR rate was significantly low in patients who had elevated levels of soluble interleukin-2 receptor (p = 0.024) and C-reactive protein (CRP; p = 0.004). The 1-year overall survival (OS) rate was 79.3%. An elevated CRP was associated with a short OS (p = 0.056). The present findings suggest that the lymphoma microenvironment and immune response were involved in the effects of bendamustine. These findings are also important in order to understand the pathophysiology of refractory lymphoma and to find effective strategies using bendamustine.


1993 ◽  
Vol 23 (4) ◽  
pp. 917-921 ◽  
Author(s):  
Claudia L. Flemming ◽  
Stephen J. Russell ◽  
Mary K. L. Collins

Author(s):  
Danièle Praseuth ◽  
Mikhaïl Grigoriev ◽  
Anne-Laure Guieysse ◽  
Linda Louise Pritchard ◽  
Annick Harel-Bellan ◽  
...  

1995 ◽  
Vol 6 (6) ◽  
pp. 737-747 ◽  
Author(s):  
Stella Dracheva ◽  
Robert E. Palermo ◽  
Gordon D. Powers ◽  
David S. Waugh

2014 ◽  
Vol 337 (1-2) ◽  
pp. 147-150 ◽  
Author(s):  
Gulibahaer Ainiding ◽  
Yuji Kawano ◽  
Shinya Sato ◽  
Noriko Isobe ◽  
Takuya Matsushita ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document